Prime Medicine, Inc. financial data

Symbol
PRME on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
21 Erie St., Cambridge, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 10, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 513 %
Debt-to-equity 26.4 %
Return On Equity -101 % +67.5%
Return On Assets -79.8 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 120M shares +23.4%
Common Stock, Shares, Outstanding 120M shares +23.4%
Entity Public Float 603M USD
Common Stock, Value, Issued 2K USD 0%
Weighted Average Number of Shares Outstanding, Basic 104M shares +17.3%
Weighted Average Number of Shares Outstanding, Diluted 104M shares +17.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 591K USD
Research and Development Expense 37.8M USD +22.3%
General and Administrative Expense 45.4M USD +38.6%
Operating Income (Loss) -213M USD -55.9%
Nonoperating Income (Expense) 8.66M USD +525%
Income Tax Expense (Benefit) 57K USD
Net Income (Loss) Attributable to Parent -204M USD -48.9%
Earnings Per Share, Basic -2.18 USD/shares +28.5%
Earnings Per Share, Diluted -2.18 USD/shares +28.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 94.2M USD -29.4%
Cash, Cash Equivalents, and Short-term Investments 211M USD -15.6%
Other Assets, Current 2.73M USD
Assets, Current 218M USD -14.1%
Property, Plant and Equipment, Net 23.9M USD +10.8%
Operating Lease, Right-of-Use Asset 55.5M USD +108%
Other Assets, Noncurrent 779K USD -52.7%
Assets 311M USD -1.76%
Accounts Payable, Current 10.1M USD +121%
Employee-related Liabilities, Current 8.27M USD +26.7%
Accrued Liabilities, Current 7.61M USD +0.92%
Liabilities, Current 24.4M USD +2.39%
Deferred Income Tax Liabilities, Net 134K USD +74%
Operating Lease, Liability, Noncurrent 37M USD +161%
Liabilities 67.6M USD +77.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -95K USD +53.7%
Retained Earnings (Accumulated Deficit) -537M USD -61.5%
Stockholders' Equity Attributable to Parent 244M USD -12.6%
Liabilities and Equity 311M USD -1.76%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -67.7M USD -62.9%
Net Cash Provided by (Used in) Financing Activities 157M USD +231263%
Net Cash Provided by (Used in) Investing Activities -37M USD -192%
Common Stock, Shares Authorized 775M shares 0%
Common Stock, Shares, Issued 120M shares +23.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 52.6M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 108M USD -26.7%
Deferred Tax Assets, Valuation Allowance 119M USD +91.9%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 123M USD +74.3%
Operating Lease, Liability 43.8M USD +68.7%
Payments to Acquire Property, Plant, and Equipment 2.32M USD +16.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -204M USD -48.6%
Lessee, Operating Lease, Liability, to be Paid 206M USD +644%
Property, Plant and Equipment, Gross 32.7M USD +28.5%
Operating Lease, Liability, Current 6.75M USD -42.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 21.3M USD +508%
Lessee, Operating Lease, Liability, to be Paid, Year One 18.6M USD +42.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure +40.7%
Deferred Income Tax Expense (Benefit) 134K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 31.9M USD +1803%
Lessee, Operating Lease, Liability, to be Paid, Year Three 20.8M USD +1137%
Deferred Tax Assets, Operating Loss Carryforwards 36M USD +76.1%
Deferred Federal Income Tax Expense (Benefit) -279K USD +11.1%
Current Income Tax Expense (Benefit) 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Four 20.9M USD +3584%
Additional Paid in Capital 781M USD +27.7%
Current State and Local Tax Expense (Benefit) 0 USD -100%
Current Federal Tax Expense (Benefit) 0 USD
Depreciation, Depletion and Amortization 4.92M USD +64.8%
Share-based Payment Arrangement, Expense 17.4M USD +149%
Deferred State and Local Income Tax Expense (Benefit) 0 USD